Board approval of the 2024 Financial statements for Medistim ASA

About this update from Medistim Asa

(Oslo, 8th of April 2025) Medistim ASA (OSE: MEDI), a niche market leaderwithin ultrasound technology with headquarter in Norway, that develops andcommercializes medical equipment for use within cardiac, vascular andtransplantsurgery, announces that the Board of Medistim ASA has approved the FinancialStatements for 2024. The Financial Statements are without changes from thepreliminary Financial Statements published on the 28th of February 2025. Theannual report for 2024 is now available. The Annual General Meeting will beheldon 8th of May 2025.About Medistim:Medistim was established in 1984, and has a track record of profitable growthover the past >15 years. The company is a pioneer within its segment andcontinues to invest in new product development. Medistim has wholly ownedsubsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark,Canada, China, Sweden and Norway, in addition to the about 60 distributors inEurope, Asia, Middle East, Africa, and South America. For more information,visit the Medistim home page: www.Medistim.comThis information is disclosed under Norwegian law (Verdipapirhandelloven§5-12).For more information, contact:President and CEO, Kari E. Krogstad, Medistim ASATel: + 47 918 38 110Email: [email protected], Thomas Jakobsen, Medistim ASATel: + 47 906 59 940Email: [email protected]://newsweb.oslobors.no/message/643235

View stock analysis, news, and events for Medistim Asa